An ongoing phase Ib clinical study (NCT03206177), is investigating the feasibility of Galunisertib in combination with carboplatin/paclitaxel, assuming that TGF-β inhibitors can inhibit EMT and increase the proportion of the carcinoma component. This evidence concerns the gene TGFB1 and carcinoma.